Radiopharm Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy at the Society for Neuro-Oncology Annual Meeting

On November 16, 2026 Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, reported that data from the Phase 2b imaging study of RAD101 in suspected recurrent brain metastases following radiotherapy were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, which took place from November 12-15, 2026 in Philadelphia, PA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We were honored to present these encouraging interim Phase 2b results at SNO before an audience of neuro-oncology experts who confront the challenge of distinguishing recurrent disease from treatment-related effects on a daily basis," said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "For clinicians caring for patients with brain metastases, uncertainty in imaging can have profound implications for treatment decisions, making the need for more accurate diagnostic tools increasingly urgent. We believe the high concordance observed between RAD101 PET/CT and MRI, together with encouraging preliminary sensitivity data and a favorable safety profile, further supports RAD101’s potential to address this critical unmet need. Following our recent alignment with the U.S. FDA on a pivotal Phase 3 imaging study, we remain focused on advancing RAD101 toward a prospective regulatory submission and are actively engaging with potential strategic partners. We look forward to reporting additional diagnostics accuracy analyses as we continue to build the evidence supporting RAD101’s differentiated value."

The Phase 2b, open-label, single-dose, single-arm, multicenter imaging study enrolled 32 participants who had suspected recurrence of previously irradiated brain metastases.

The primary endpoint was concordance with MRI, which had high patient-level agreement between 18F-RAD101 PET/CT and contrast-enhanced MRI at 93.5% for all-lesion detection. For the secondary endpoint, among the 16 participants evaluable against the reference standard (histopathology or longitudinal MRI follow-up) at the interim analysis, sensitivity was 85.7%.. No treatment-emergent serious adverse events or clinically significant laboratory or ECG abnormalities were observed. The company plans on reporting additional diagnostic accuracy data and complete diagnostic follow up in 2027.

RAD101 has received FDA Fast Track Designation to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal disease. The company has also announced a partnership with Siemens Healthineers, who will manufacture and distribute doses of 18F-labeled RAD101 to support the upcoming Phase 3 registrational trial in the U.S.

In the U.S. alone, there are more than 300,000 patients diagnosed annually with brain metastases. The incidence of Intracranial Metastatic Disease (IMD) continues to increase, in part, due to improvements in systemic therapy resulting in a more durable control of the tumors outside of the central nervous system. Contrast-enhanced Magnetic Resonance Imaging (CE-MRI) is the preferred method for imaging IMD, but has limitations, particularly in follow-up surveillance scans to optimise patient care.1

About RAD101

RAD101 is an ¹⁸F-labelled fatty acid analogue that images FASN-associated fatty acid metabolism in brain metastases. (FASN) is a multi-enzyme protein that catalyses de novo fatty acid synthesis and is overexpressed in brain metastases from solid tumors. Targeting FASN activity may allow for the more accurate detection of cancer cells in the CNS, representing a clinically relevant method for the imaging of brain metastases. Positive data from the Imperial College London’s Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases (both SRS pre-treated and treatment naïve patients) showed significant tumor uptake that was independent from the tumor of origin. The study further indicated that PET-MRI may provide non-invasive prediction of overall survival, warranting larger studies.

(Press release, Radiopharm Theranostics, NOV 16, 2026, View Source [SID1234674855])

Evotec secures $2.9 million grant to advance early drug safety testing

On November 16, 2026 Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) reported that it has been awarded a new $2.9 million grant by the Gates Foundation to support continued use of its human stem cell-based New Approach Methodologies (NAMs) for identifying potential safety risks to fetal development in novel drug candidates. The funding extends a project initiated in 2023 for a further three years, providing researchers working on global health programs with continued access to technology that can help assess potential risks earlier in drug discovery.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Joanna Holbrook, Chief Scientific Officer of Evotec, said:

"Identifying potential safety risks early in the drug development process is essential to the efficient advancement of better medicines for global health priorities. Our platform allows researchers to investigate potential effects on prenatal development based on the behavior of human cells, helping them make better-informed decisions about which drug candidates to pursue and minimizing the risk of costly and time-consuming changes in course later in the process. The continued funding support of the Gates Foundation is an important recognition of the potential value of this approach, and we are pleased to extend access to this technology for global health research."

Evotec’s platform combines human induced pluripotent stem cell (hiPSC) models with industrial-scale screening capabilities to model aspects of human development and to identify compounds that may pose developmental risks.

Over the course of the initial three-year collaboration, more than 5,000 compounds were screened across nine grantee programs, highlighting the platform’s ability to generate human-relevant safety data at scale. The development and validation of the platform are described in a recent bioRxiv preprint.

Evotec’s human stem cell-based platform forms part of its broader capabilities in New Approach Methodologies, which can potentially reduce reliance on animal testing and help improve research efficiency.

(Press release, Evotec, NOV 16, 2026, View Source [SID1234674807])

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

On November 16, 2026 Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, reported financial results for the quarter ended September 30, 2026, and highlighted new clinical findings supporting mipletamig’s potential in frontline acute myeloid leukemia (AML), progress in optimizing treatment tolerability, and continued advancement of its next-generation cancer treatment pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline," said Jeff Lamothe, President and Chief Executive Officer of Aptevo. "We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability. Each of these findings adds a new dimension to the mipletamig story and strengthens our conviction in its potential to become an important addition to frontline AML treatment. At the same time, we are advancing a new generation of cancer therapies designed to bring the power of our multispecific technology to more patients and more types of cancer. As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders."

Business Highlights

Mipletamig delivers a 79% remission rate in one of the hardest-to-treat forms of AML, nearly double a published historical benchmark. In September, Aptevo reported that 14 evaluable TP53-mutated patients treated with mipletamig in combination with venetoclax and azacitidine, including two patients from the previously completed dose expansion trial, 13 (93%) experienced clinical benefit. * Eleven patients achieved CR or CRi (79%), including nine complete remissions.
*Clinical benefit includes complete remission (CR), complete remission with incomplete hematologic recovery (CRi), partial response (PR) and morphologic leukemia-free state (MLFS).

These results are encouraging because patients with TP53-mutated AML have historically had limited treatment success. The 79% CR/CRi rate observed in evaluable patients treated with the mipletamig triplet compares favorably with a published 41% composite remission rate of intent-to-treat, treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML who received only venetoclax plus azacitidine.**

**Benchmark comparison based on Pollyea DA, et al. Clinical Cancer Research. 2022;28(24):5272-5279. Comparison is to treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML treated with venetoclax plus azacitidine.

Ten of 47 patients receiving mipletamig combination therapy advances to potentially curative stem cell transplantation. In October, Aptevo reported that ten of 47 evaluable frontline patients treated with mipletamig in combination with venetoclax and azacitidine (VEN+AZA) proceeded to allogeneic stem cell transplantation, a potentially curative treatment option. This includes nine patients from the ongoing Phase 1b RAINIER trial and one patient from the previously completed dose expansion trial. This finding is particularly encouraging in a patient population initially deemed unfit for intensive induction chemotherapy, where advanced age, underlying health conditions and other factors can limit treatment options.
Aptevo significantly reduced infusion-related reactions through refinements to mipletamig’s priming-dose regimen. The adjustment substantially improved tolerability, addressing an important clinical development priority. For patients already facing the challenges of AML treatment, fewer reactions may mean a more manageable treatment experience, while supporting continued advancement toward Phase 2.
Mipletamig approaches a major development milestone as RAINIER nears completion of Phase 1b dose optimization. With study completion targeted by year-end 2026 and regulatory interaction planned for the first half of 2027, Aptevo is moving closer to the next phase of clinical development, bringing mipletamig another step toward its potential role in frontline AML treatment.
Aptevo clears important development hurdles on the path toward human testing of its next generation trispecifics. Progress in manufacturing optimization supports the ability to produce therapeutics that perform more than one immune engaging job in a single molecule – reliably and at the scale needed for further development. This moves Aptevo closer to advancing new treatment candidates for solid tumors, expanding its opportunities beyond AML.
Aptevo expands the potential of its technology to power multiple new cancer treatments. A new patent application covering Nectin-4 × PD-L1 dual-targeting technology could support both immune-based therapies and radiopharmaceuticals. The filing strengthens Aptevo’s intellectual property strategy, creating opportunities to apply its technology across multiple cancer treatment approaches.
Aptevo secures $4.5 million in additional financing to support its next development milestones. In August, existing warrant holders exercised warrants for 254,922 shares at a price of $4.03 per share and purchased 861,708 additional shares (or pre-funded warrants) at the same price in a private placement. Investors also received new warrants covering up to 5,583,150 shares at $4.03 per share, which would provide up to $22.5 million in additional proceeds if exercised. The transaction provides additional capital to advance mipletamig and the Company’s next-generation pipeline, helping fund continued clinical and preclinical progress.
Third Quarter 2026 Financials

Cash position: Cash and cash equivalents totaled $8.3 million as of September 30, 2026, compared with $9.8 million as of June 30, 2026.
Net loss: Net loss for the third quarter of 2026 was $6.5 million, compared with $7.5 million for the third quarter of 2025.
Financing activity: In August 2026, the company completed a warrant inducement and private placement that generated gross proceeds of approximately $4.5 million, or approximately $4.1 million net of $0.4 million in issuance costs.
For additional APVO financial information and complete access to the company’s filings, click here.

(Press release, Aptevo Therapeutics, NOV 16, 2026, View Source [SID1234674824])

Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer

On November 16, 2026 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to onvansertib in combination with FOLFIRI/bevacizumab (bev) for the first-line treatment of adult patients with KRAS- or NRAS-mutated metastatic colorectal cancer (mCRC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need," said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. "Our randomized Phase 2 data give us confidence that onvansertib may provide an additive benefit to the current standard-of-care, as reflected in the maturing data from the ongoing trial. We look forward to working closely with the FDA as we advance onvansertib into our planned registrational trial and bringing this potential new treatment option to patients as quickly as possible."

The Fast Track designation is supported by data from the Company’s ongoing randomized Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC. The proposed Phase 3 regimen, 30 mg onvansertib + FOLFIRI/bev, achieved a 72.2% confirmed objective response rate, a 30-point improvement over FOLFIRI/bev alone (42.1%) in the intent-to-treat population. As of September 28, 2026, median progression-free survival had not been reached in the 30 mg arm, compared with approximately 11 months in the combined standard-of-care arms, and all patients remaining in the 30 mg arm have now been on treatment for at least 21 months. These results build on a prior Phase 1b/2 trial in second-line KRAS-mutated mCRC.

This designation also follows the FDA’s recent grant of Orphan Drug Designation to onvansertib for the treatment of chronic myelomonocytic leukemia and small cell lung cancer in October and November 2026, respectively.

About Fast Track Designation

Fast Track is an FDA program designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and address an unmet medical need. A drug that receives Fast Track designation may be eligible for more frequent meetings and written communication with the FDA regarding its development plan, and, if relevant criteria are met, for Accelerated Approval and Priority Review. Fast Track designation also allows for Rolling Review, under which a company may submit completed sections of its marketing application for FDA review rather than waiting until every section is complete. Fast Track designation does not alter the standards for approval.

About Onvansertib

Onvansertib is a highly specific, oral PLK1 inhibitor advancing toward a registrational trial in first-line RAS-mutated metastatic colorectal cancer (mCRC). In a randomized Phase 2 trial, onvansertib in combination with FOLFIRI/bevacizumab (first-line standard-of-care) demonstrated dose-dependent improvements in overall response rate and progression-free survival compared to standard-of-care alone, building on findings from a prior Phase 1b/2 trial in second-line KRAS-mutated mCRC. Based on these results, the Company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab as the regimen to advance into the planned registrational trial in first-line patients with RAS-mutated mCRC.

Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC) and triple-negative breast cancer (TNBC), as well as chronic myelomonocytic leukemia (CMML) and small cell lung cancer (SCLC), both of which have received FDA Orphan Drug Designation.

About RAS-Mutated Metastatic Colorectal Cancer (mCRC)

Colorectal cancer is among the most commonly diagnosed cancers and the second-leading cause of cancer deaths in the United States, with approximately 150,000 new cases each year1. About 23% of patients have metastatic disease at diagnosis, and the five-year relative survival rate for mCRC is approximately 15%2. Mutations in the KRAS or NRAS genes occur in approximately 52% of patients with mCRC and are associated with poorer outcomes. Patients with RAS-mutated mCRC are not candidates for anti-EGFR therapies, and first-line treatment has remained largely unchanged for two decades: chemotherapy combined with bevacizumab. There are currently no therapies specifically approved for first-line pan-RAS-mutated mCRC, highlighting the need for new treatments that can improve outcomes for this population.

(Press release, Cardiff Oncology, NOV 16, 2026, View Source [SID1234674856])

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®

On November 16, 2026 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) reported that following the contract renewal with the China National Healthcare Security Administration ("NHSA"), the updated National Reimbursement Drug List ("NRDL") effective on January 1, 2027 will continue to include ELUNATE, ORPATHYS and SULANDA. This update reflects expanded coverage for new indications, renewed agreements for existing indications, as well as continued inclusion under current multi-year agreements.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Newly Included and Renewed Indications in the Updated NRDL:

● ELUNATE (fruquintinib) is newly included for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor ("VEGFR") tyrosine kinase inhibitors ("TKI") therapy and have not received programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor therapy in the first-line setting, in combination with sintilimab injection.

● ORPATHYS (savolitinib) is newly included for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor ("EGFR") mutation-positive non-squamous non-small cell lung cancer ("NSCLC") with MET amplification after disease progression on EGFR-TKI therapy, in combination with osimertinib. It is also renewed for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration.

In addition to the above updates, the NRDL maintains coverage for all other previously included indications for ELUNATE, ORPATHYS and SULANDA under their current multi-year agreement.

The government in China has placed great importance on improving the affordability of drug treatments for the public. As of end of 2025, 1.33 billion people in China had basic medical insurance coverage, representing around 95% of the entire population. The NRDL is updated every year, and inclusion on the list is subject to renewal every two years. The NHSA annually convenes a broad network of experts in medicine, pharmacology, pharmacoeconomics and actuarial valuation to identify innovative medicines to consider for NRDL inclusion. Reimbursement of Category B medicines, including novel oncology medicines, requires varying degrees of copayment from patients, depending on their provinces or types of NHSA insurance scheme enrollment.

About Fruquintinib

Fruquintinib is a selective oral inhibitor of all three VEGFR -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA.

About Savolitinib

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS.

About Surufatinib

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA. HUTCHMED currently retains all rights to surufatinib worldwide.

(Press release, Hutchison China MediTech, NOV 16, 2026, View Source [SID1234674808])